Thank you Ole, and thank you all for joining our call. Our second quarter results reflect improving but still weak demand and the extremely challenging price-cost dynamics in our paper business, resulting in $170 million of adjusted EBITDA, $59 million of free cash flow, and adjusted EPS of $0.82 per share. As Ole mentioned, we are leaning on the Greif business system to serve our customers with excellence, manage costs, and diligently monitor our business for signs of an inflection. The Greif business system champions for continuous improvement, accelerates plant modernization and automation, as well as creates value through gemba and Six Sigma programs. Using these tools, we continue to drive structural cost out and build productivity gains that not only help optimize our current business but also provides the foundation to accelerate integration and synergy capture as we grow through acquisitions. While managing the present, we are also growing for the future through the Ipackchem acquisition and through high value capital projects, such as our recently opened Dallas sheetfeeder. These investments are critical to our long term vision and strategy and will position us well for outperformance once markets return to a normalized state. We are reinstating the guidance range given our confidence in our view of the remainder of our fiscal year. We are pleased to raise the low end from our prior $610 million to $675 million and add a high end of $725 million. Before discussing guidance assumptions, let me provide a segment performance update, starting on Slide 9. For GIP, continuing weak but improving demand led to a year-over-year sales decline of $57 million and margin compression of 1.5% year-over-year. In addition, SG&A costs were up year-over-year, in line with our expectations communicated in our Q4 call. This was primarily a result of D&A step-up on new acquisitions as well as our ongoing strategic investments in IT and global operating excellence which, while expensed, we view as strategic capital we are investing for long term margin improvement. Despite the incremental cost of these investments, margins rallied strongly by over 4.4% on a sequential basis from fiscal Q1 2024. As Ole touched on, EMEA continued to improve, underpinned by strong lube and chemical markets. The Americas remained flat to down as lube and chemical demand improvement has not yet been seen; however, North America has seen overall sequential improvement and we do anticipate that recovery to continue into the second half of our fiscal year. Please turn to Slide 10 for PPS results. The continued delayed recognition of announced pricing increases combined with the rising OCC cost has led to a significant margin compression of over 10% despite flat sales. Our PPS team is continuing to manage controllables well, including successful price increase implementation on our non-index based customers. However, the outsized impact of the index-driven price-cost dynamic, which we still view to not be in sync with real market trends, is a headwind we have and will continue to aggressively work to offset. On the volume side in containerboard, we are seeing modest improvement, while the tube and core end markets remain flat to down. While managing the present, we are also continuing to invest in the future within this product group, resulting in SG&A cost inflation for a similar strategic initiative, as discussed, with GIP. Please turn to Slide 11 for our updated guidance and outlook. As previously stated, we are providing a guidance EBITDA range of $675 million to $725 million, reflecting an increase of $65 million on the low end. The high end of our guidance range reflects recognition of our announced paper price increases, as well as continued margin improvement in GIP. By contrast, the low end of our guidance range assumes no paper price recognition, slight further OCC cost inflation, and no margin improvement in GIP. On the volume side, our guidance change of $22 million to $62 million of EBITDA assumes further contribution of the improving volume trends across most of our products and end markets. As Ole mentioned earlier, our incremental EBITDA contribution from Ipackchem is less than previously disclosed run rate due to a full year impact of purchase accounting of $8.4 million, as well as short term slowness in the global ag markets. Lastly, we anticipate volume-related as well as inflationary transport and manufacturing headwinds of $19 million to $39 million of EBITDA relative to prior guidance. As for free cash flow, we are leaving our previous guidance unchanged at our midpoint at $200 million for the full year. We anticipate that the increase in our EBITDA guidance midpoint of $90 million will not result in incremental cash flow within fiscal ’24. The drivers of this are at the midpoint higher spend on strategic capex and efficiency-related maintenance projects for $20 million, higher cash interest primarily related to the acquisition of Ipackchem of $25 million, higher cash taxes of $26 million related to improved earnings as well as the failure of Congress to extend favorable tax provisions, higher working capital needs to address improving demand of $32 million partially offset by a favorable $13 million of other miscellaneous cash items. As Ole mentioned in his remarks, while we continue to monitor our business near term, it is critical we also maintain a long term lens and invest for the future. As such, I would like to discuss capital allocation on Slide 12. Under build-to-last, which we define as fiscal ’22 through present, we have deployed over $2.6 billion of capital. Our capital allocation framework is simple: we first invest in two non-negotiables, our safety and maintenance capex which keeps our cash machine running, and our regular and increasing dividend. While critical, these uses are not a significant portion of total cash generated in that same time frame, and so the rest we devoted towards growing our business and increasing shareholder return. On the growth side, the recent majority has come through developing the leading global small plastics platform which Ole discussed in his remarks. The long term benefits of this business are substantial and we are encourage by our successful execution of the transactions, our integration progress and synergy realization. We balanced growth with debt reduction at times when it is necessary to temporarily increase our leverage above our long term target of leverage ratio in the range of 2 to 2.5 times in order to capitalize on long term value-accretive growth opportunities, such as Ipackchem. Given our current leverage, we anticipate in the short term prioritizing incremental debt reduction. We have confidence in the value creation benefits of our capital deployment under build-to-last, and we’ll plan to dive deeper into this topic at our upcoming investor day in December. With that, I’ll turn things back to Ole for closing on Slide 13.